Neuropathic Pain – Current Treatment – Treatment Algorithms: Claims Data Analysis – Postherpetic Neuralgia (US)
Postherpetic neuralgia (PHN) is characterized by itching, numbness, and burning, as well as stabbing, shooting, or shock-like pain. PHN is managed with multiple established, generic antiepileptic drugs (e.g., gabapentin, pregabalin), antidepressants (e.g., amitriptyline, duloxetine), and dual-acting opioid analgesics (e.g., tramadol), as well as topical lidocaine (e.g., Scilex’s ZTLido) and topical capsaicin (e.g., Averitas’s Qutenza). However, current analgesics fall short in providing adequate relief due to side effects, prolonged titration, inadequate dosing, poor compliance, and low treatment satisfaction. Thus, unmet need and opportunity exist for new options, particularly those with novel mechanisms of action. The successful launch of a novel analgesic for PHN or other form of neuropathic pain will require a granular understanding of treatment patterns in PHN, a common gateway market for emerging neuropathic pain drugs.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PHN patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PHN patients?
- How have branded agents offering incremental safety, tolerability, or dosing benefits fared in this highly generic market? How have they been integrated into the treatment algorithm, and what is their source of business?
- What percentage of PHN patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of PHN patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What is the product-level compliance and persistency rates among drug-treated patients?
Geography: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs: gabapentin, pregabalin, Qutenza, ZTLido, Gralise, Horizant, amitriptyline, duloxetine, venlafaxine, milnacipran, topiramate, opioids, tramadol, tapentadol
Key analyses: Brand / therapy usage across longitudinal patient sample, Newly diagnosed patient analysis, Treatment initiation and progression, Line of therapy analysis, Combination therapy analysis, Source of business for recently treated patients, Persistency and compliance analysis, Product-level patient flow charts
Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses.
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
